{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:27:21Z","timestamp":1790108841580,"version":"4.0.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute kidney injury (AKI) in paediatric kidney transplant recipients is common. Infection including urinary tract infection (UTI) and rejection are the most common causes in children. Surgical complications often cause AKI early post-transplant, whereas BK polyomavirus nephropathy rarely occurs in the first month post-transplant. Understanding kidney physiology helps to appreciate the sensitivity of the allograft to AKI, more so than native kidneys. Although the cause of AKI is often multi-factorial, there may be an underlying process that is treatable. Eliciting the aetiology, in this regard, is of paramount importance. Pre-renal and post-renal causes of allograft dysfunction are important to distinguish from intrinsic kidney disease. Clinical information and examination of fluid balance, urine dipstick testing, blood tests, bladder and kidney transplant ultrasound, and kidney transplant biopsy remain vital assessment tools in narrowing the differential diagnosis. A careful prescribed and recreational drug history is always warranted as many drugs including supplements are nephrotoxic. Additional causes such as allograft rejection, recurrent disease, and calcineurin inhibitor toxicity need to be considered in cases of allograft dysfunction, which would not affect the native kidneys. Early detection and assessment of AKI is crucial in promoting recovery. Significant progress has been made in specific pathologies over the last 20\u00a0years, which has improved kidney allograft survival rates considerably. Research into identifying AKI biomarkers to assist early diagnosis, before the serum creatinine rises, is ongoing.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s00467-025-06655-y","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:13:38Z","timestamp":1738091618000},"page":"2161-2175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute kidney injury in paediatric kidney transplant recipients"],"prefix":"10.1007","volume":"40","author":[{"given":"Barian","family":"Mohidin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"6655_CR1","doi-asserted-by":"publisher","unstructured":"(2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Supp 2:19\u201336. https:\/\/doi.org\/10.1038\/kisup.2011.32","DOI":"10.1038\/kisup.2011.32"},{"key":"6655_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3343\/alm.2021.41.1.1","volume":"41","author":"C Albert","year":"2021","unstructured":"Albert C, Haase M, Albert A et al (2021) Biomarker-guided risk assessment for acute kidney injury: time for clinical implementation? Ann Lab Med 41:1\u201315. https:\/\/doi.org\/10.3343\/alm.2021.41.1.1","journal-title":"Ann Lab Med"},{"key":"6655_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00467-018-4087-z","volume":"34","author":"N Ziegelasch","year":"2019","unstructured":"Ziegelasch N, Vogel M, M\u00fcller E et al (2019) Cystatin C serum levels in healthy children are related to age, gender, and pubertal stage. Pediatr Nephrol 34:449\u2013457. https:\/\/doi.org\/10.1007\/s00467-018-4087-z","journal-title":"Pediatr Nephrol"},{"key":"6655_CR4","doi-asserted-by":"publisher","unstructured":"Chen DC, Potok OA, Rifkin D, Estrella MM (2022) Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR. Kidney360 3:1807\u20131814. https:\/\/doi.org\/10.34067\/KID.0003202022","DOI":"10.34067\/KID.0003202022"},{"key":"6655_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2215\/CJN.02440218","volume":"13","author":"O Alkandari","year":"2018","unstructured":"Alkandari O, Nguyen L, Hebert D et al (2018) Acute kidney injury in children with klidney transplantation. Clin J Am Soc Nephrol 13:1721\u20131729. https:\/\/doi.org\/10.2215\/CJN.02440218","journal-title":"Clin J Am Soc Nephrol"},{"key":"6655_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000486744","volume":"43","author":"E Rodr\u00edguez","year":"2018","unstructured":"Rodr\u00edguez E, Arias-Cabrales C, Bermejo S et al (2018) Impact of recurrent acute kidney injury on patient outcomes. Kidney Blood Press Res 43:34\u201344. https:\/\/doi.org\/10.1159\/000486744","journal-title":"Kidney Blood Press Res"},{"key":"6655_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/jcm10071484","volume":"10","author":"A Palmisano","year":"2021","unstructured":"Palmisano A, Gandolfini I, Delsante M et al (2021) Acute kidney injury (AKI) before and after kidney transplantation: causes, medical approach, and implications for the long-term outcomes. J Clin Med 10:1484. https:\/\/doi.org\/10.3390\/jcm10071484","journal-title":"J Clin Med"},{"key":"6655_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/01.hyp.12.2.168","volume":"12","author":"RJ Roman","year":"1988","unstructured":"Roman RJ, Cowley AW, Garcia-Esta\u00f1 J, Lombard JH (1988) Pressure-diuresis in volume-expanded rats. Cortical Medullary Hemodynamics Hypertens 12:168\u2013176. https:\/\/doi.org\/10.1161\/01.hyp.12.2.168","journal-title":"Cortical Medullary Hemodynamics Hypertens"},{"key":"6655_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.59.3.347","volume":"59","author":"H Goldblatt","year":"1934","unstructured":"Goldblatt H, Lynch J, Hanzal RF, Summerville WW (1934) Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347\u2013379. https:\/\/doi.org\/10.1084\/jem.59.3.347","journal-title":"J Exp Med"},{"key":"6655_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/01.hyp.29.4.1025","volume":"29","author":"P Wiesel","year":"1997","unstructured":"Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T (1997) Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension 29:1025\u20131030. https:\/\/doi.org\/10.1161\/01.hyp.29.4.1025","journal-title":"Hypertension"},{"key":"6655_CR11","first-page":"43","volume":"1","author":"H Ismail","year":"1997","unstructured":"Ismail H, Kalici\u0144ski P, Drewniak T et al (1997) Primary vascular thrombosis after renal transplantation in children. Pediatr Transplant 1:43\u201347","journal-title":"Pediatr Transplant"},{"key":"6655_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/tri.12660","volume":"29","author":"RR Redfield","year":"2016","unstructured":"Redfield RR, McCune KR, Rao A et al (2016) Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transpl Int 29:167\u2013172. https:\/\/doi.org\/10.1111\/tri.12660","journal-title":"Transpl Int"},{"key":"6655_CR13","doi-asserted-by":"publisher","first-page":"e0251036","DOI":"10.1371\/journal.pone.0251036","volume":"16","author":"A Velioglu","year":"2021","unstructured":"Velioglu A, Guneri G, Arikan H et al (2021) Incidence and risk factors for urinary tract infections in the first year after renal transplantation. PLoS One 16:e0251036. https:\/\/doi.org\/10.1371\/journal.pone.0251036","journal-title":"PLoS One"},{"key":"6655_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.euros.2023.04.001","volume":"52","author":"ACL Halskov","year":"2023","unstructured":"Halskov ACL, Dagn\u00e6s-Hansen J, Stroomberg HV et al (2023) Incidence of and risk factors for recurrent urinary tract infections in renal transplant recipients. Eur Urol Open Sci 52:115\u2013122. https:\/\/doi.org\/10.1016\/j.euros.2023.04.001","journal-title":"Eur Urol Open Sci"},{"key":"6655_CR15","doi-asserted-by":"publisher","first-page":"953139","DOI":"10.3389\/fped.2022.953139","volume":"10","author":"E Spiwak","year":"2022","unstructured":"Spiwak E, Nailescu C, Schwaderer A (2022) Pediatric kidney transplant recipients with and without underlying structural kidney disease have a comparable risk of hospitalization associated with urinary tract infections. Front Pediatr 10:953139. https:\/\/doi.org\/10.3389\/fped.2022.953139","journal-title":"Front Pediatr"},{"key":"6655_CR16","doi-asserted-by":"publisher","unstructured":"Shendi AM, Wallis G, Painter H et al (2018) Epidemiology and impact of bloodstream infections among kidney transplant recipients: a retrospective single-center experience. Transpl Infect Dis 20. https:\/\/doi.org\/10.1111\/tid.12815","DOI":"10.1111\/tid.12815"},{"key":"6655_CR17","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.juro.2007.01.054","volume":"177","author":"M Herthelius","year":"2007","unstructured":"Herthelius M, Oborn H (2007) Urinary tract infections and bladder dysfunction after renal transplantation in children. J Urol 177:1883\u20131886. https:\/\/doi.org\/10.1016\/j.juro.2007.01.054","journal-title":"J Urol"},{"key":"6655_CR18","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/ndt\/15.11.1852","volume":"15","author":"B Ranchin","year":"2000","unstructured":"Ranchin B, Chapuis F, Dawhara M et al (2000) Vesicoureteral reflux after kidney transplantation in children. Nephrol Dial Transplant 15:1852\u20131858. https:\/\/doi.org\/10.1093\/ndt\/15.11.1852","journal-title":"Nephrol Dial Transplant"},{"key":"6655_CR19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciad009","volume":"76","author":"J McAteer","year":"2023","unstructured":"McAteer J, Lee JH, Cosgrove SE et al (2023) Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated bacteremia. Clin Infect Dis 76:1604\u20131612. https:\/\/doi.org\/10.1093\/cid\/ciad009","journal-title":"Clin Infect Dis"},{"key":"6655_CR20","doi-asserted-by":"publisher","unstructured":"M Brownlee E, Blore C, Wragg R et al (2020) D-Mannose reduces the risk of UTI in complex paediatric urology patients. Arch Pediatr 5:180. https:\/\/doi.org\/10.29011\/2575-825X.100180","DOI":"10.29011\/2575-825X.100180"},{"key":"6655_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jac\/4.4.355","volume":"4","author":"J Elo","year":"1978","unstructured":"Elo J, Sarna S, Ahava K, Lepo A (1978) Methenamine hippurate in urinary tract infections in children: prophylaxis, treatment and side effects. J Antimicrob Chemother 4:355\u2013365. https:\/\/doi.org\/10.1093\/jac\/4.4.355","journal-title":"J Antimicrob Chemother"},{"key":"6655_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/TP.0000000000002414","volume":"103","author":"B H\u00f6cker","year":"2019","unstructured":"H\u00f6cker B, Schneble L, Murer L et al (2019) Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an international CERTAIN registry study. Transplantation 103:1224\u20131233. https:\/\/doi.org\/10.1097\/TP.0000000000002414","journal-title":"Transplantation"},{"key":"6655_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","volume":"108","author":"CN Kotton","year":"2024","unstructured":"Kotton CN, Kamar N, Wojciechowski D et al (2024) The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation 108:1834\u20131866. https:\/\/doi.org\/10.1097\/TP.0000000000004976","journal-title":"Transplantation"},{"key":"6655_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1399-3046.2012.01732.x","volume":"16","author":"D Matossian","year":"2012","unstructured":"Matossian D, Langman CB, Cohn RA, Ali FN (2012) Obstructive uropathy is associated with polyomavirus viremia in pediatric kidney transplantation. Pediatr Transplant 16:729\u2013734. https:\/\/doi.org\/10.1111\/j.1399-3046.2012.01732.x","journal-title":"Pediatr Transplant"},{"key":"6655_CR25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.kint.2021.12.020","volume":"101","author":"I Batal","year":"2022","unstructured":"Batal I, Morris HK (2022) The case | Late allograft dysfunction with unexpected biopsy findings. Kidney Int 101:1307\u20131308. https:\/\/doi.org\/10.1016\/j.kint.2021.12.020","journal-title":"Kidney Int"},{"key":"6655_CR26","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1111\/j.1600-6143.2007.01984.x","volume":"7","author":"F Ginevri","year":"2007","unstructured":"Ginevri F, Azzi A, Hirsch HH et al (2007) Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 7:2727\u20132735. https:\/\/doi.org\/10.1111\/j.1600-6143.2007.01984.x","journal-title":"Am J Transplant"},{"key":"6655_CR27","doi-asserted-by":"publisher","first-page":"e13460","DOI":"10.1111\/petr.13460","volume":"23","author":"Y Hamasaki","year":"2019","unstructured":"Hamasaki Y, Dolan NM, Cubitt D et al (2019) BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant 23:e13460. https:\/\/doi.org\/10.1111\/petr.13460","journal-title":"Pediatr Transplant"},{"key":"6655_CR28","first-page":"178","volume":"9","author":"M Launay","year":"2018","unstructured":"Launay M, Baudouin V, Guillemain R et al (2018) Leflunomide for BK virus: report of seven kidney-transplanted children. Int J Organ Transplant Med 9:178\u2013183","journal-title":"Int J Organ Transplant Med"},{"key":"6655_CR29","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1111\/j.1399-3046.2010.01384.x","volume":"16","author":"EI Anyaegbu","year":"2012","unstructured":"Anyaegbu EI, Almond PS, Milligan T et al (2012) Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant 16:e19\u2013e24. https:\/\/doi.org\/10.1111\/j.1399-3046.2010.01384.x","journal-title":"Pediatr Transplant"},{"key":"6655_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00007890-200301150-00020","volume":"75","author":"A Vats","year":"2003","unstructured":"Vats A, Shapiro R, Singh Randhawa P et al (2003) Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75:105\u2013112. https:\/\/doi.org\/10.1097\/00007890-200301150-00020","journal-title":"Transplantation"},{"key":"6655_CR31","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ajt.15723","volume":"20","author":"N Leeaphorn","year":"2020","unstructured":"Leeaphorn N, Thongprayoon C, Chon WJ et al (2020) Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents. Am J Transplant 20:1334\u20131340. https:\/\/doi.org\/10.1111\/ajt.15723","journal-title":"Am J Transplant"},{"key":"6655_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/TP.0b013e31822d08c1","volume":"92","author":"D Geetha","year":"2011","unstructured":"Geetha D, Sozio SM, Ghanta M et al (2011) Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation 92:781\u2013786. https:\/\/doi.org\/10.1097\/TP.0b013e31822d08c1","journal-title":"Transplantation"},{"key":"6655_CR33","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/j.1600-6143.2010.03083.x","volume":"10","author":"VR Dharnidharka","year":"2010","unstructured":"Dharnidharka VR, Cherikh WS, Neff R et al (2010) Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 10:1312\u20131315. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03083.x","journal-title":"Am J Transplant"},{"key":"6655_CR34","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/TP.0000000000000888","volume":"100","author":"B H\u00f6cker","year":"2016","unstructured":"H\u00f6cker B, Zencke S, Krupka K et al (2016) Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-) Ganciclovir. Transplantation 100:862\u2013870. https:\/\/doi.org\/10.1097\/TP.0000000000000888","journal-title":"Transplantation"},{"key":"6655_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2009111188","volume":"21","author":"JM Smith","year":"2010","unstructured":"Smith JM, Corey L, Bittner R et al (2010) Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21:1579\u20131586. https:\/\/doi.org\/10.1681\/ASN.2009111188","journal-title":"J Am Soc Nephrol"},{"key":"6655_CR36","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/TP.0b013e3181a492e8","volume":"87","author":"LA Danziger-Isakov","year":"2009","unstructured":"Danziger-Isakov LA, Worley S, Michaels MG et al (2009) The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation 87:1541\u20131548. https:\/\/doi.org\/10.1097\/TP.0b013e3181a492e8","journal-title":"Transplantation"},{"key":"6655_CR37","doi-asserted-by":"publisher","first-page":"e13573","DOI":"10.1111\/tid.13573","volume":"23","author":"H Stamps","year":"2021","unstructured":"Stamps H, Linder K, O\u2019Sullivan DM et al (2021) Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte-depleting induction. Transpl Infect Dis 23:e13573. https:\/\/doi.org\/10.1111\/tid.13573","journal-title":"Transpl Infect Dis"},{"key":"6655_CR38","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM et al (2018) The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 102:900\u2013931. https:\/\/doi.org\/10.1097\/TP.0000000000002191","journal-title":"Transplantation"},{"key":"6655_CR39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/ajt.13649","volume":"16","author":"B H\u00f6cker","year":"2016","unstructured":"H\u00f6cker B, Zencke S, Pape L et al (2016) Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation. Am J Transplant 16:921\u2013929. https:\/\/doi.org\/10.1111\/ajt.13649","journal-title":"Am J Transplant"},{"key":"6655_CR40","doi-asserted-by":"publisher","first-page":"1197828","DOI":"10.3389\/fped.2023.1197828","volume":"11","author":"M Panesso","year":"2023","unstructured":"Panesso M, Ur\u00eda ML, Renedo B et al (2023) CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation. Front Pediatr 11:1197828. https:\/\/doi.org\/10.3389\/fped.2023.1197828","journal-title":"Front Pediatr"},{"key":"6655_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/rmv.574","volume":"18","author":"S Chou","year":"2008","unstructured":"Chou S (2008) Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 18:233\u2013246. https:\/\/doi.org\/10.1002\/rmv.574","journal-title":"Rev Med Virol"},{"key":"6655_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jcv.2010.01.009","volume":"47","author":"M Martin","year":"2010","unstructured":"Martin M, Goyette N, Ives J, Boivin G (2010) Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 47:321\u2013324. https:\/\/doi.org\/10.1016\/j.jcv.2010.01.009","journal-title":"J Clin Virol"},{"key":"6655_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ajt.14557","volume":"18","author":"A Hart","year":"2018","unstructured":"Hart A, Smith JM, Skeans MA et al (2018) OPTN\/SRTR 2016 Annual Data Report: Kidney. Am J Transplant 18:18\u2013113. https:\/\/doi.org\/10.1111\/ajt.14557","journal-title":"Am J Transplant"},{"key":"6655_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","volume":"18","author":"M Haas","year":"2018","unstructured":"Haas M, Loupy A, Lefaucheur C et al (2018) The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18:293\u2013307. https:\/\/doi.org\/10.1111\/ajt.14625","journal-title":"Am J Transplant"},{"key":"6655_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.14107","volume":"17","author":"A Loupy","year":"2017","unstructured":"Loupy A, Haas M, Solez K et al (2017) The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant 17:28\u201341. https:\/\/doi.org\/10.1111\/ajt.14107","journal-title":"Am J Transplant"},{"key":"6655_CR46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2215\/CJN.11991019","volume":"15","author":"JE Cooper","year":"2020","unstructured":"Cooper JE (2020) Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol 15:430\u2013438. https:\/\/doi.org\/10.2215\/CJN.11991019","journal-title":"Clin J Am Soc Nephrol"},{"key":"6655_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ki.2009.377","volume":"77","author":"BL Kasiske","year":"2010","unstructured":"Kasiske BL, Zeier MG, Chapman JR et al (2010) KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77:299\u2013311. https:\/\/doi.org\/10.1038\/ki.2009.377","journal-title":"Kidney Int"},{"key":"6655_CR48","doi-asserted-by":"publisher","first-page":"e14617","DOI":"10.1111\/petr.14617","volume":"28","author":"A Landsberg","year":"2024","unstructured":"Landsberg A, Raza SS, Seifert ME, Blydt-Hansen TD (2024) Follow-up biopsies identify high rates of persistent rejection in pediatric kidney transplant recipients after treatment of T cell-mediated rejection. Pediatr Transplant 28:e14617. https:\/\/doi.org\/10.1111\/petr.14617","journal-title":"Pediatr Transplant"},{"key":"6655_CR49","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","volume":"102","author":"C Roufosse","year":"2018","unstructured":"Roufosse C, Simmonds N, Clahsen-van Groningen M et al (2018) A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 102:1795\u20131814. https:\/\/doi.org\/10.1097\/TP.0000000000002366","journal-title":"Transplantation"},{"key":"6655_CR50","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","volume":"20","author":"A Loupy","year":"2020","unstructured":"Loupy A, Haas M, Roufosse C et al (2020) The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell\u2013 and antibody-mediated rejection. Am J Transplant 20:2318\u20132331. https:\/\/doi.org\/10.1111\/ajt.15898","journal-title":"Am J Transplant"},{"key":"6655_CR51","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","volume":"14","author":"M Haas","year":"2014","unstructured":"Haas M, Sis B, Racusen LC et al (2014) Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14:272\u2013283. https:\/\/doi.org\/10.1111\/ajt.12590","journal-title":"Am J Transplant"},{"key":"6655_CR52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/ajt.12150","volume":"13","author":"J Sellar\u00e9s","year":"2013","unstructured":"Sellar\u00e9s J, Reeve J, Loupy A et al (2013) Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 13:971\u2013983. https:\/\/doi.org\/10.1111\/ajt.12150","journal-title":"Am J Transplant"},{"key":"6655_CR53","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1681\/ASN.2013111149","volume":"25","author":"A Loupy","year":"2014","unstructured":"Loupy A, Lefaucheur C, Vernerey D et al (2014) Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 25:2267\u20132277. https:\/\/doi.org\/10.1681\/ASN.2013111149","journal-title":"J Am Soc Nephrol"},{"key":"6655_CR54","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00467-011-1864-3","volume":"26","author":"B Kranz","year":"2011","unstructured":"Kranz B, Kelsch R, Kuwertz-Br\u00f6king E et al (2011) Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 26:1149\u20131156. https:\/\/doi.org\/10.1007\/s00467-011-1864-3","journal-title":"Pediatr Nephrol"},{"key":"6655_CR55","doi-asserted-by":"publisher","unstructured":"Rom\u00e1n-Ortiz E, Mendizabal S (2015) Eculizumab in antibody-mediated rejection of paediatric renal transplantation. Nephrol Dial Transplant 30:iii671\u2013iii672. https:\/\/doi.org\/10.1093\/ndt\/gfv203.32","DOI":"10.1093\/ndt\/gfv203.32"},{"key":"6655_CR56","doi-asserted-by":"publisher","unstructured":"Kizilbash S, Claes D, Ashoor I et al (2017) Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: a multicenter Midwest Pediatric Nephrology Consortium study. Pediatr Transplant 21(3). https:\/\/doi.org\/10.1111\/petr.12873","DOI":"10.1111\/petr.12873"},{"key":"6655_CR57","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1016\/j.transproceed.2020.06.022","volume":"52","author":"M Okada","year":"2020","unstructured":"Okada M, Tomosugi T, Futamura K et al (2020) Mid-term outcomes after treatment for antibody-mediated rejection by de novo donor-specific HLA antibody in renal transplant recipients: does early treatment lead to better outcomes? Transplant Proc 52:3051\u20133057. https:\/\/doi.org\/10.1016\/j.transproceed.2020.06.022","journal-title":"Transplant Proc"},{"key":"6655_CR58","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1399-3046.2009.01281.x","volume":"14","author":"PS Verghese","year":"2010","unstructured":"Verghese PS, Smith JM, McDonald RA et al (2010) Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant 14:730\u2013734. https:\/\/doi.org\/10.1111\/j.1399-3046.2009.01281.x","journal-title":"Pediatr Transplant"},{"key":"6655_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00467-022-05582-6","volume":"38","author":"M Matsuda-Abedini","year":"2023","unstructured":"Matsuda-Abedini M, Marks SD, Foster BJ (2023) Transition of young adult kidney transplant recipients. Pediatr Nephrol 38:383\u2013390. https:\/\/doi.org\/10.1007\/s00467-022-05582-6","journal-title":"Pediatr Nephrol"},{"key":"6655_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","volume":"94","author":"M Willicombe","year":"2012","unstructured":"Willicombe M, Brookes P, Sergeant R et al (2012) De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 94:172\u2013177. https:\/\/doi.org\/10.1097\/TP.0b013e3182543950","journal-title":"Transplantation"},{"key":"6655_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/TP.0b013e3181880b35","volume":"86","author":"H Billing","year":"2008","unstructured":"Billing H, Rieger S, Ovens J et al (2008) Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 86:1214\u20131221. https:\/\/doi.org\/10.1097\/TP.0b013e3181880b35","journal-title":"Transplantation"},{"key":"6655_CR62","doi-asserted-by":"publisher","first-page":"e14853","DOI":"10.1111\/ctr.14853","volume":"37","author":"P Khairallah","year":"2023","unstructured":"Khairallah P, Robbins-Juarez S, Patel S et al (2023) Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients. Clin Transplant 37:e14853. https:\/\/doi.org\/10.1111\/ctr.14853","journal-title":"Clin Transplant"},{"key":"6655_CR63","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s00467-017-3725-1","volume":"32","author":"Y Cihan","year":"2017","unstructured":"Cihan Y, Kanzelmeyer N, Drube J et al (2017) Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation. Pediatr Nephrol 32:2133\u20132142. https:\/\/doi.org\/10.1007\/s00467-017-3725-1","journal-title":"Pediatr Nephrol"},{"key":"6655_CR64","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","volume":"104","author":"CA Schinstock","year":"2020","unstructured":"Schinstock CA, Mannon RB, Budde K et al (2020) Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation 104:911\u2013922. https:\/\/doi.org\/10.1097\/TP.0000000000003095","journal-title":"Transplantation"},{"key":"6655_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk SS, Rein JL (2020) The many faces of calcineurin inhibitor toxicity\u2014what the FK? Adv Chronic Kidney Dis 27:56\u201366. https:\/\/doi.org\/10.1053\/j.ackd.2019.08.006","journal-title":"Adv Chronic Kidney Dis"},{"key":"6655_CR66","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1056\/NEJMra033540","volume":"351","author":"PF Halloran","year":"2004","unstructured":"Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715\u20132729. https:\/\/doi.org\/10.1056\/NEJMra033540","journal-title":"N Engl J Med"},{"key":"6655_CR67","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/01.tp.0000128636.70499.6e","volume":"78","author":"BJ Nankivell","year":"2004","unstructured":"Nankivell BJ, Borrows RJ, Fung CLS et al (2004) Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78:557\u2013565. https:\/\/doi.org\/10.1097\/01.tp.0000128636.70499.6e","journal-title":"Transplantation"},{"key":"6655_CR68","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","volume":"81","author":"DS Genest","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C et al (2023) Renal thrombotic microangiopathy: a review. Am J Kidney Dis 81:591\u2013605. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.014","journal-title":"Am J Kidney Dis"},{"key":"6655_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41100-022-00453-0","volume":"9","author":"K Ozaki","year":"2023","unstructured":"Ozaki K, Fukawa T, Yamaguchi K et al (2023) Drug-induced de novo thrombotic microangiopathy diagnosed 2 years after renal transplantation: a case report and literature review. Ren Replace Ther 9:1. https:\/\/doi.org\/10.1186\/s41100-022-00453-0","journal-title":"Ren Replace Ther"},{"key":"6655_CR70","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","volume":"30","author":"G Cortina","year":"2015","unstructured":"Cortina G, Trojer R, Waldegger S et al (2015) De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. Pediatr Nephrol 30:693\u2013697. https:\/\/doi.org\/10.1007\/s00467-014-3036-8","journal-title":"Pediatr Nephrol"},{"key":"6655_CR71","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.transproceed.2016.04.005","volume":"48","author":"J Merola","year":"2016","unstructured":"Merola J, Yoo PS, Schaub J et al (2016) Belatacept and Eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: case report. Transplant Proc 48:3106\u20133108. https:\/\/doi.org\/10.1016\/j.transproceed.2016.04.005","journal-title":"Transplant Proc"},{"key":"6655_CR72","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","volume":"12","author":"P Archdeacon","year":"2012","unstructured":"Archdeacon P, Dixon C, Belen O et al (2012) Summary of the US FDA approval of Belatacept. Am J Transplant 12:554\u2013562. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03976.x","journal-title":"Am J Transplant"},{"key":"6655_CR73","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1681\/ASN.2014050429","volume":"26","author":"JS Chua","year":"2015","unstructured":"Chua JS, Baelde HJ, Zandbergen M et al (2015) Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 26:2239\u20132247. https:\/\/doi.org\/10.1681\/ASN.2014050429","journal-title":"J Am Soc Nephrol"},{"key":"6655_CR74","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","volume":"96","author":"BL Laskin","year":"2013","unstructured":"Laskin BL, Maisel J, Goebel J et al (2013) Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 96:217\u2013223. https:\/\/doi.org\/10.1097\/TP.0b013e31829807aa","journal-title":"Transplantation"},{"key":"6655_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trim.2018.03.002","volume":"49","author":"HB Cazarote","year":"2018","unstructured":"Cazarote HB, Shimakura S, Valdameri JS et al (2018) Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure. Transpl Immunol 49:33\u201338. https:\/\/doi.org\/10.1016\/j.trim.2018.03.002","journal-title":"Transpl Immunol"},{"key":"6655_CR76","doi-asserted-by":"publisher","first-page":"e5147","DOI":"10.7759\/cureus.5147","volume":"11","author":"M Gangireddy","year":"2019","unstructured":"Gangireddy M, Shrimanker I, Saintelia S, Nookala VK (2019) Active hepatitis C leading to refractory thrombotic thrombocytopenic ourpura\u2014a dubious association and the challenges faced in management. Cureus 11:e5147. https:\/\/doi.org\/10.7759\/cureus.5147","journal-title":"Cureus"},{"key":"6655_CR77","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/tri.12582","volume":"28","author":"A Java","year":"2015","unstructured":"Java A, Edwards A, Rossi A et al (2015) Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int 28:1121\u20131125. https:\/\/doi.org\/10.1111\/tri.12582","journal-title":"Transpl Int"},{"key":"6655_CR78","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4103\/0972-5229.183903","volume":"20","author":"T Dineshkumar","year":"2016","unstructured":"Dineshkumar T, Dhanapriya J, Jaganathan P et al (2016) Thrombotic microangiopathy as an initial manifestation in HIV patients. Indian J Crit Care Med 20:374\u2013376. https:\/\/doi.org\/10.4103\/0972-5229.183903","journal-title":"Indian J Crit Care Med"},{"key":"6655_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1291\/hypres.28.89","volume":"28","author":"Y Shibagaki","year":"2005","unstructured":"Shibagaki Y, Fujita T (2005) Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)\/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res 28:89\u201395. https:\/\/doi.org\/10.1291\/hypres.28.89","journal-title":"Hypertens Res"},{"key":"6655_CR80","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","volume":"98","author":"D Matar","year":"2014","unstructured":"Matar D, Naqvi F, Racusen LC et al (2014) Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 98:1205\u20131212. https:\/\/doi.org\/10.1097\/TP.0000000000000200","journal-title":"Transplantation"},{"key":"6655_CR81","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","volume":"30","author":"CM Legendre","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T et al (2017) Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int 30:1275\u20131283. https:\/\/doi.org\/10.1111\/tri.13022","journal-title":"Transpl Int"},{"key":"6655_CR82","doi-asserted-by":"publisher","first-page":"e13152","DOI":"10.1111\/ctr.13152","volume":"32","author":"S Cormican","year":"2018","unstructured":"Cormican S, Kennedy C, O\u2019Kelly P et al (2018) Renal transplant outcomes in primary FSGS compared with other recipients and risk factors for recurrence: a national review of the Irish Transplant Registry. Clin Transplant 32:e13152. https:\/\/doi.org\/10.1111\/ctr.13152","journal-title":"Clin Transplant"},{"key":"6655_CR83","first-page":"246","volume":"104","author":"L Laplante","year":"1975","unstructured":"Laplante L, Beaudry C, Houde M (1975) Early disappearance of proteinuria attributed to the original kidneys after kidney transplantation. L\u2019union medicale du Canada 104:246\u2013248","journal-title":"L\u2019union medicale du Canada"},{"key":"6655_CR84","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.kint.2023.10.017","volume":"105","author":"R Raina","year":"2024","unstructured":"Raina R, Jothi S, Haffner D et al (2024) Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements. Kidney Int 105:450\u2013463. https:\/\/doi.org\/10.1016\/j.kint.2023.10.017","journal-title":"Kidney Int"},{"key":"6655_CR85","doi-asserted-by":"publisher","first-page":"e13955","DOI":"10.1111\/petr.13955","volume":"25","author":"LT Weber","year":"2021","unstructured":"Weber LT, T\u00f6nshoff B, Grenda R et al (2021) Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis\/steroid-resistant nephrotic syndrome. Pediatr Transplant 25:e13955. https:\/\/doi.org\/10.1111\/petr.13955","journal-title":"Pediatr Transplant"},{"key":"6655_CR86","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/ctr.12825","volume":"30","author":"R Cleper","year":"2016","unstructured":"Cleper R, Krause I, Bar Nathan N et al (2016) Focal segmental glomerulosclerosis in pediatric kidney transplantation: 30 years\u2019 experience. Clin Transplant 30:1324\u20131331. https:\/\/doi.org\/10.1111\/ctr.12825","journal-title":"Clin Transplant"},{"key":"6655_CR87","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/TP.0b013e31819f12be","volume":"87","author":"LJ Hickson","year":"2009","unstructured":"Hickson LJ, Gera M, Amer H et al (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87:1232\u20131239. https:\/\/doi.org\/10.1097\/TP.0b013e31819f12be","journal-title":"Transplantation"},{"key":"6655_CR88","doi-asserted-by":"publisher","first-page":"32087","DOI":"10.1038\/srep32087","volume":"6","author":"X Shen","year":"2016","unstructured":"Shen X, Jiang H, Ying M et al (2016) Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 6:32087. https:\/\/doi.org\/10.1038\/srep32087","journal-title":"Sci Rep"},{"key":"6655_CR89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12882-022-02768-w","volume":"23","author":"JM Restrepo","year":"2022","unstructured":"Restrepo JM, Torres-Canchala L, Londo\u00f1o H et al (2022) Treatment of post-transplant recurrent FSGS in children using plasmapheresis and augmentation of immunosuppression. BMC Nephrol 23:131. https:\/\/doi.org\/10.1186\/s12882-022-02768-w","journal-title":"BMC Nephrol"},{"key":"6655_CR90","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.1993.324","volume":"44","author":"J Laine","year":"1993","unstructured":"Laine J, Jalanko H, Holth\u00f6fer H et al (1993) Post-transplantation nephrosis in congenital nephrotic syndrome of the Finnish type. Kidney Int 44:867\u2013874. https:\/\/doi.org\/10.1038\/ki.1993.324","journal-title":"Kidney Int"},{"key":"6655_CR91","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/01.tp.0000262569.27890.64","volume":"83","author":"A-M Kuusniemi","year":"2007","unstructured":"Kuusniemi A-M, Qvist E, Sun Y et al (2007) Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1). Transplantation 83:1316\u20131323. https:\/\/doi.org\/10.1097\/01.tp.0000262569.27890.64","journal-title":"Transplantation"},{"key":"6655_CR92","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/s0272-6386(03)00364-0","volume":"41","author":"R Bertelli","year":"2003","unstructured":"Bertelli R, Ginevri F, Caridi G et al (2003) Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 41:1314\u20131321. https:\/\/doi.org\/10.1016\/s0272-6386(03)00364-0","journal-title":"Am J Kidney Dis"},{"key":"6655_CR93","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","volume":"100","author":"A Grupper","year":"2016","unstructured":"Grupper A, Cornell LD, Fervenza FC et al (2016) Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications. Transplantation 100:2710\u20132716. https:\/\/doi.org\/10.1097\/TP.0000000000001056","journal-title":"Transplantation"},{"key":"6655_CR94","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100:S1\u2013S276https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"6655_CR95","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-015-0219-x","volume":"17","author":"S Alasfar","year":"2016","unstructured":"Alasfar S, Carter-Monroe N, Rosenberg AZ et al (2016) Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol 17:7. https:\/\/doi.org\/10.1186\/s12882-015-0219-x","journal-title":"BMC Nephrol"},{"key":"6655_CR96","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00467-014-2839-y","volume":"29","author":"A S\u00e1nchez-Moreno","year":"2014","unstructured":"S\u00e1nchez-Moreno A, De la Cerda F, Cabrera R et al (2014) Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 29:2055\u20132059. https:\/\/doi.org\/10.1007\/s00467-014-2839-y","journal-title":"Pediatr Nephrol"},{"key":"6655_CR97","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa2021712","journal-title":"N Engl J Med"},{"key":"6655_CR98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum MA, Langman C, Cochat P et al (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207\u2013217. https:\/\/doi.org\/10.1016\/j.kint.2022.07.025","journal-title":"Kidney Int"},{"key":"6655_CR99","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/TP.0b013e31821ab9aa","volume":"91","author":"D Geetha","year":"2011","unstructured":"Geetha D, Eirin A, True K et al (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 91:1370\u20131375. https:\/\/doi.org\/10.1097\/TP.0b013e31821ab9aa","journal-title":"Transplantation"},{"key":"6655_CR100","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1093\/ndt\/gfp347","volume":"24","author":"MA Little","year":"2009","unstructured":"Little MA, Hassan B, Jacques S et al (2009) Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant 24:3219\u20133225. https:\/\/doi.org\/10.1093\/ndt\/gfp347","journal-title":"Nephrol Dial Transplant"},{"key":"6655_CR101","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12882-022-02802-x","volume":"23","author":"C J\u00e4ger","year":"2022","unstructured":"J\u00e4ger C, Stampf S, Molyneux K et al (2022) Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. BMC Nephrol 23:178. https:\/\/doi.org\/10.1186\/s12882-022-02802-x","journal-title":"BMC Nephrol"},{"key":"6655_CR102","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1432-2277.2009.00966.x","volume":"23","author":"SS Han","year":"2010","unstructured":"Han SS, Huh W, Park SK et al (2010) Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int 23:169\u2013175. https:\/\/doi.org\/10.1111\/j.1432-2277.2009.00966.x","journal-title":"Transpl Int"},{"key":"6655_CR103","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"6655_CR104","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A et al (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402:859\u2013870. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"6655_CR105","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2215\/CJN.00520111","volume":"6","author":"N Kanaan","year":"2011","unstructured":"Kanaan N, Mourad G, Thervet E et al (2011) Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis. Clin J Am Soc Nephrol 6:1768\u20131772. https:\/\/doi.org\/10.2215\/CJN.00520111","journal-title":"Clin J Am Soc Nephrol"},{"key":"6655_CR106","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1523-1755.2004.00428.x","volume":"65","author":"G Browne","year":"2004","unstructured":"Browne G, Brown PAJ, Tomson CRV et al (2004) Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 65:675\u2013681. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00428.x","journal-title":"Kidney Int"},{"key":"6655_CR107","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.kint.2020.07.050","volume":"98","author":"GL Irish","year":"2020","unstructured":"Irish GL, Hesselman P, Pedchenko VK et al (2020) The case | A 23-year-old male with hemoptysis. Kidney Int 98:1627\u20131628. https:\/\/doi.org\/10.1016\/j.kint.2020.07.050","journal-title":"Kidney Int"},{"key":"6655_CR108","doi-asserted-by":"publisher","first-page":"121","DOI":"10.52964\/AMJA.0761","volume":"18","author":"B Mohidin","year":"2019","unstructured":"Mohidin B, Bass P, Salama A, Hamour S (2019) Malignant renal obstruction without dilatation. Acute Med 18:121\u2013123","journal-title":"Acute Med"},{"key":"6655_CR109","unstructured":"Aeddula NR, Baradhi KM (2023) Reflux nephropathy. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)"},{"key":"6655_CR110","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.kint.2021.11.034","volume":"101","author":"L Bu","year":"2022","unstructured":"Bu L, Gupta G, Pai A et al (2022) Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. Kidney Int 101:793\u2013803. https:\/\/doi.org\/10.1016\/j.kint.2021.11.034","journal-title":"Kidney Int"},{"key":"6655_CR111","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2215\/CJN.03840322","volume":"17","author":"R Dandamudi","year":"2022","unstructured":"Dandamudi R, Gu H, Goss CW et al (2022) Longitudinal evaluation of donor-derived cellfree DNA in pediatric kidney transplantation. Clin J Am Soc Nephrol 17:1646\u20131655. https:\/\/doi.org\/10.2215\/CJN.03840322","journal-title":"Clin J Am Soc Nephrol"},{"key":"6655_CR112","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/j.1600-6143.2010.03201.x","volume":"10","author":"LG Hidalgo","year":"2010","unstructured":"Hidalgo LG, Sis B, Sellares J et al (2010) NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 10:1812\u20131822. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03201.x","journal-title":"Am J Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06655-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:18:01Z","timestamp":1748337481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":112,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6655"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06655-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}